ATLANTA, Ga., October 21, 2024 – Odylia Therapeutics, a pioneering nonprofit biotechnology company focused on accelerating therapeutics for rare diseases, is excited to announce the appointment of Elizabeth Attias to its Board of Directors, effective immediately.

With nearly 30 years of experience in the biotechnology and pharmaceutical sectors, Elizabeth brings a wealth of knowledge in strategic planning, portfolio growth, operational excellence, and alliance building. She has a proven track record of driving innovation and growth with cross functional expertise in pharma, biotech, and consulting, making her a valuable addition to Odylia’s leadership team.

“Elizabeth’s extensive background in the life sciences industry with companies from startup phase through to commercial programs and her commitment to advancing therapeutic solutions will enhance the depth of expertise on Odylia’s Board and help us continue to fulfill our mission,” said Ashley Winslow, CEO and CSO of Odylia Therapeutics. “We are confident that her insights and leadership will significantly contribute to our continued growth and success as we work to bring transformative therapies to patients in need.”

Elizabeth is President and CEO of Atom Strategic Consulting and Chief Strategy and Development Officer at Sermonix Pharmaceuticals, a precision oncology biotech. Prior to working at Atom and Sermonix, Elizbeth worked at Parke-Davis Pharmaceuticals where she led multiple product launches and spearheaded Medical Affairs and Medical Scientific Liaison efforts.  She is known for her strategic vision and ability to foster collaborative partnerships that drive innovation and enhance patient outcomes.

“I am thrilled to join the Board of Directors at Odylia Therapeutics,” said Elizabeth Attias.” I was inspired by Odylia’s leadership, science, and the company’s passionate goal to bring life changing treatments to people with genetic disease regardless of prevalence or commercial interest. Odylia’s innovative and unique, nonprofit business model to accelerate the development of gene therapies for people with rare disease, will change the way treatments are brought from the lab to the clinic. I look forward to working alongside such a talented team to advance our mission and make a meaningful impact on patients’ lives.”

Elizabeth holds a Doctor of Science (Sc.D.) from Johns Hopkins University and a Masters of Medical Science (M.M.Sc) from Emory University. She is actively involved in various industry organizations, where she advocates for advancements in healthcare and biotechnology.

For more information about Odylia Therapeutics and its innovative approaches to rare disease treatment, please visit odylia.org

—

Media Contact:

For media inquiries, please contact:
Odylia Media
info@odylia.org

About Odylia Therapeutics

Odylia is a nonprofit biotech focused on bringing life-altering and lifesaving treatments to those with rare diseases. With expertise in both preclinical and clinical drug development for rare diseases, Odylia seeks to change how drugs are developed for rare diseases by focusing on the science and patient needs, rather than the commercial potential. Odylia partners with patient communities, researchers, clinicians, industry, and financial donors to bring promising therapeutics to clinical trials. In addition to two gene therapies in development, Odylia partners with rare disease patient groups, early-stage gene therapy companies, and academic researchers to further rare disease drug development efforts through Odylia’s Brydge Solutions program. Patient groups, companies, and researchers interested in learning more about Odylia Therapeutics’ services can email info@odylia.org and Odylia on LinkedIn (Odylia Therapeutics), Instagram (@OdyliaTx), and YouTube (@OdyliaTx), and Facebook (Odylia Therapeutics). For additional information, visit https://odylia.org.